HYLA™ blood sensor intends to reduce the need for actual blood
samples to be taken from patients
RA'ANANA, Israel, July 6, 2022
/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd.
(NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira
Technologies"), a groundbreaking respiratory support technology
company, revealed the development of the HYLA™ blood sensor.
Without the need to take actual blood samples from patients,
Inspira's non-invasive optical blood sensor is being designed to
perform real-time and continuous blood monitoring to alert
physicians of immediate signs of changes in a patient's clinical
condition. The HYLA blood sensor is targeting the potential
$2.5 billion Point of Care testing,
ABG (Arterial Blood Gas) analyzer market.
Optical sensor based on machine-learning algorithms
The non-invasive HYLA blood sensor is being developed by a
team of cyber-warfare specialists who formerly served in the
Israeli Defense Forces' elite cyber-attack special forces. The HYLA
blood sensor is being designed as a new platform based on key
technologies being developed for Inspira's ART™ system, designed to
reduce the need for invasive mechanical ventilation. Like the ART
system, the HYLA blood sensor is designed to minimize the need for
invasive medical procedures with the intention of reducing risks,
complications and costs.
Expanding Market Growth Opportunities
The HYLA™
non-invasive blood sensor is attached to the outer walls of a tube
that has blood flowing through it. The HYLA blood sensor may have
broad application potential, benefiting patients undergoing
procedures including intensive care unit (ICU) monitoring
(approximately 40% of patients have a standard arterial line),
Invasive Mechanical Ventilation, Extracorporeal Membrane
Oxygenation (ECMO), Dialysis and Cardiopulmonary bypass. Targeted
patient populations can potentially include those suffering from
acute respiratory failure, cardiac failure, pneumonia, acute kidney
injury (AKI), as well as patients undergoing open-heart
surgery.
Real-time patient monitoring can potentially save
lives
Currently, in order to identify changes in a patient's
medical condition, frequent invasive blood tests are needed. As a
non-invasive real-time blood sensor, the HYLA is expected to reduce
the need for frequent invasive blood tests.
The HYLA blood sensor is expected to continuously measure
several key indicators such as the levels of partial oxygen and
carbon dioxide pressures, known to be precise indicators of health
disorders and patient deterioration.
Dagi Ben-Noon, Inspira™ Technologies' Chief Executive
Officer, stated:
"Inspira Technologies has set out to
change the way we monitor patient health. Today, hospital patients
are reliant on physicians manually monitoring their health
condition with invasive blood tests, as much as several times a
day. We believe that the HYLA blood sensor has the potential to
change patient experience and outcomes, through the non-invasive
blood sensor, that is intended to perform real-time and continuous
blood monitoring, with the intention of alerting physicians of
changes in a patient's clinical condition that could potentially
save lives."
This technology has not been tested or used in humans and is
subject to regulatory approval.
Inspira Technologies OXY B.H.N. Ltd.
Inspira
Technologies is an innovative medical technology company in the
respiratory treatment arena. The Company has developed a
breakthrough Augmented Respiration Technology (ART), designed to
rebalance patient oxygen saturation levels. The Company's ART™
technology potentially allows patients to remain awake during
treatment while minimizing the need for highly invasive, risky, and
costly mechanical ventilation systems that require intubation and
medically induced coma. The Company's product has not yet been
tested or used in humans and has not been approved by any
regulatory entity.
For more information, please visit our corporate
website:
https://inspira-technologies.com/
Forward-Looking Statement Disclaimer
This press
release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking
statements and their implications are based on the current
expectations of the management of the Company only and are subject
to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the potential design
and function of the HYLA™ blood sensor, the potential benefits that
may be realized through the use of the HYLA™ blood sensor, that the
HYLA™ blood sensor is being designed to target the "Point of Care"
testing, ABG (Arterial Blood Gas) analyzer market, and the
potential size of that market, and that Inspira™ Technologies
has set out to change the way patient health is monitored. These
forward-looking statements and their implications are based solely
on the current expectations of the Company's management and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Except as otherwise required by law,
the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2021
filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website, www.sec.gov
For more details:
US Investor Relations
Miri Segal,
MS-IR LLC
+917-607-8654
US Public Relations
Dave
Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
IINN@redchip.com
MRK-ARS-026
Copyright © 2018-2022 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Photo:
https://mma.prnewswire.com/media/1853436/HYLA_Blood_Sensor.jpg
Logo:
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inspira-technologies-develops-a-non-invasive-blood-sensor-designed-to-alert-real-time-change-in-patients---potentially-targets-2-5-billion-abg-market-301581383.html
SOURCE Inspira Technologies